Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Looks For Sepsis Biomarkers That Could Aid Xigris Administration

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies are underway to support the use of protein C as a biomarker, Lilly Senior Medical Director for Cardiovascular & Acute Care Macias tells a recent CDER seminar. Data suggest Xigris, a form of activated protein C, has higher survival rates when administered early. Biomarkers could be a signal for use.

You may also be interested in...



Lilly Xigris Trial Will Use Biomarker To Tailor Treatment

Partner Biosite will develop a rapid protein C diagnostic to be used in the Phase IIb trial, which is set to begin in the fourth quarter of 2006.

Lilly Xigris Trial Will Use Biomarker To Tailor Treatment

Partner Biosite will develop a rapid protein C diagnostic to be used in the Phase IIb trial, which is set to begin in the fourth quarter of 2006.

Xigris "Dear Doctor" Letter Follows Termination Of Pediatric Sepsis Trial

Lilly says a data monitoring committee determined that Xigris was "highly unlikely to show improvement over placebo" in the study's primary endpoint – composite time to complete organ failure resolution.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel